MedTrace Logo

Herbal Mouthrinse for Oral Mucositis Study

NCT01898091 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-03-06

Study results available
· View outcomes & findings →

Summary

This study involves adults receiving radiation therapy for head and neck cancer and will test whether or not the study mouthrinse may lessen oral mucositis.

Conditions

  • Oral Mucositis

Interventions

DRUG

Neem Mouthrinse

10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.

DRUG

Placebo Mouthrinse

10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Susan G. Reed, DDS, DrPH · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898091 on ClinicalTrials.gov